Logo image of ALBLU.PA

BLUELINEA (ALBLU.PA) Stock Fundamental Analysis

EPA:ALBLU - FR0011041011 - Common Stock

0.472 EUR
0 (0%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

1

Overall ALBLU gets a fundamental rating of 1 out of 10. We evaluated ALBLU against 57 industry peers in the Health Care Equipment & Supplies industry. ALBLU may be in some trouble as it scores bad on both profitability and health. ALBLU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ALBLU had negative earnings in the past year.
ALBLU had a positive operating cash flow in the past year.
In the past 5 years ALBLU always reported negative net income.
ALBLU had negative operating cash flow in 4 of the past 5 years.
ALBLU.PA Yearly Net Income VS EBIT VS OCF VS FCFALBLU.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -13.54%, ALBLU is doing worse than 68.42% of the companies in the same industry.
ALBLU's Return On Equity of -89.94% is on the low side compared to the rest of the industry. ALBLU is outperformed by 80.70% of its industry peers.
Industry RankSector Rank
ROA -13.54%
ROE -89.94%
ROIC N/A
ROA(3y)-13.4%
ROA(5y)-23.48%
ROE(3y)-62.07%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALBLU.PA Yearly ROA, ROE, ROICALBLU.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

The Gross Margin of ALBLU (104.45%) is better than 98.25% of its industry peers.
In the last couple of years the Gross Margin of ALBLU has grown nicely.
The Profit Margin and Operating Margin are not available for ALBLU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 104.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.37%
GM growth 5Y2.44%
ALBLU.PA Yearly Profit, Operating, Gross MarginsALBLU.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

More info and screens

0

2. Health

2.1 Basic Checks

ALBLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALBLU has about the same amount of shares outstanding.
The number of shares outstanding for ALBLU has been increased compared to 5 years ago.
The debt/assets ratio for ALBLU is higher compared to a year ago.
ALBLU.PA Yearly Shares OutstandingALBLU.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ALBLU.PA Yearly Total Debt VS Total AssetsALBLU.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

ALBLU has an Altman-Z score of -2.89. This is a bad value and indicates that ALBLU is not financially healthy and even has some risk of bankruptcy.
ALBLU's Altman-Z score of -2.89 is on the low side compared to the rest of the industry. ALBLU is outperformed by 82.46% of its industry peers.
ALBLU has a Debt/Equity ratio of 2.17. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.17, ALBLU is doing worse than 84.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF N/A
Altman-Z -2.89
ROIC/WACCN/A
WACC6.82%
ALBLU.PA Yearly LT Debt VS Equity VS FCFALBLU.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M 8M

2.3 Liquidity

ALBLU has a Current Ratio of 0.50. This is a bad value and indicates that ALBLU is not financially healthy enough and could expect problems in meeting its short term obligations.
ALBLU has a worse Current ratio (0.50) than 91.23% of its industry peers.
ALBLU has a Quick Ratio of 0.50. This is a bad value and indicates that ALBLU is not financially healthy enough and could expect problems in meeting its short term obligations.
ALBLU has a Quick ratio of 0.44. This is amonst the worse of the industry: ALBLU underperforms 87.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.5
Quick Ratio 0.44
ALBLU.PA Yearly Current Assets VS Current LiabilitesALBLU.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.92% over the past year.
The Revenue has decreased by -3.84% in the past year.
Measured over the past years, ALBLU shows a quite strong growth in Revenue. The Revenue has been growing by 8.42% on average per year.
EPS 1Y (TTM)20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.89%
Revenue 1Y (TTM)-3.84%
Revenue growth 3Y7.87%
Revenue growth 5Y8.42%
Sales Q2Q%-1.24%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALBLU.PA Yearly Revenue VS EstimatesALBLU.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ALBLU.PA Yearly EPS VS EstimatesALBLU.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALBLU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALBLU.PA Price Earnings VS Forward Price EarningsALBLU.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

ALBLU's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 18.39
ALBLU.PA Per share dataALBLU.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALBLU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUELINEA

EPA:ALBLU (9/5/2025, 7:00:00 PM)

0.472

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners83.76%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap8.69M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.92
P/FCF N/A
P/OCF 10.13
P/B 6.16
P/tB N/A
EV/EBITDA 18.39
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)0.05
OCFY9.87%
SpS0.51
BVpS0.08
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.54%
ROE -89.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 104.45%
FCFM N/A
ROA(3y)-13.4%
ROA(5y)-23.48%
ROE(3y)-62.07%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.37%
GM growth 5Y2.44%
F-Score5
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF N/A
Debt/EBITDA 4.55
Cap/Depr 107.65%
Cap/Sales 21.23%
Interest Coverage N/A
Cash Conversion 127.13%
Profit Quality N/A
Current Ratio 0.5
Quick Ratio 0.44
Altman-Z -2.89
F-Score5
WACC6.82%
ROIC/WACCN/A
Cap/Depr(3y)146.58%
Cap/Depr(5y)113.61%
Cap/Sales(3y)22.56%
Cap/Sales(5y)17.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.89%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.84%
Revenue growth 3Y7.87%
Revenue growth 5Y8.42%
Sales Q2Q%-1.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y68.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y233.13%
OCF growth 3YN/A
OCF growth 5YN/A